Syncona's Nightstar Begins NSR-REP1 Trial And Appoints New Director
5th Mar 2018 13:07
LONDON (Alliance News) - Healthcare-focused investment company Syncona Ltd said on Monday that portfolio company Nightstar Therapeutics PLC has initiated a STAR Phase Three to Read More